ProCE Banner Activity

CDK4/6 Inhibitors for Premenopausal and Postmenopausal Women With HR-Positive/HER2-Negative Advanced Breast Cancer

Slideset Download
Review the latest clinical data and expert guidance on leveraging CDK4/6 inhibitors for treatment of HR+/HER2- advanced breast cancer, including how to select among available agents and manage common toxicities.

Released: June 17, 2020

Expiration: June 16, 2021

Share

Faculty

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California